Clinical trials: Cognitive Deterioration
SARS-CoV-2 Infection, Cognitive Change
The ACDC Study Assessing Cognitive Deterioration in COVID-19
The long-term impact and effects of COVID-19 are still being determined. However, what is clear, is that some people are still struggling following a period of illness with COVID-19.
- Conditions
- SARS-CoV-2 Infection, Cognitive Change, Cognitive Dysfunction
- Trial name
- ACDC (NCT05855434)
- Testing
- Magnetic Resonance Imaging
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- NHS Grampian
Leukodystrophies
Natural History of the Leukodystrophies
The purpose of this study is to: 1. define novel homogeneous groups of patients with LDs and 2. work toward finding the cause of these disorders.
- Trial name
- NCT02843555
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor Research Institute
Disseminated Sclerosis
A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein).
In multiple sclerosis (MS) sub cortical cognitive impairments are frequently reported. Nevertheless, cortical cognitive troubles, with hippocampic memory troubles have been described.
- Trial name
- BioCogS (NCT00978536)
- Testing
- Cognitive impairment of multiple sclerosis
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Nantes University Hospital